BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Breast cancer
ERBB2
Molecular subtyping
Monoclonal antibodies
Predictive biomarkers
Response prediction
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
19 06 2023
19 06 2023
Historique:
received:
15
11
2022
accepted:
25
05
2023
medline:
21
6
2023
pubmed:
20
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
The introduction of pertuzumab has greatly improved pathological complete response (pCR) rates in HER2-positive breast cancer, yet effects on long-term survival have been limited and it is uncertain which patients derive most benefit. In this study, we determine the prognostic value of BluePrint subtyping in HER2-positive breast cancer. Additionally, we evaluate its use as a biomarker for predicting response to trastuzumab-containing neoadjuvant chemotherapy with or without pertuzumab. From a cohort of patients with stage II-III HER2-positive breast cancer who were treated with neoadjuvant chemotherapy and trastuzumab with or without pertuzumab, 836 patients were selected for microarray gene expression analysis, followed by readout of BluePrint standard (HER2, Basal and Luminal) and dual subtypes (HER2-single, Basal-single, Luminal-single, HER2-Basal, Luminal-HER2, Luminal-HER2-Basal). The associations between subtypes and pathological complete response (pCR), overall survival (OS) and breast cancer-specific survival (BCSS) were assessed, and pertuzumab benefit was evaluated within the BluePrint subgroups. BluePrint results were available for 719 patients. In patients with HER2-type tumors, the pCR rate was 71.9% in patients who received pertuzumab versus 43.5% in patients who did not (adjusted Odds Ratio 3.43, 95% CI 2.36-4.96). Additionally, a significantly decreased hazard was observed for both OS (adjusted hazard ratio [aHR] 0.45, 95% CI 0.25-0.80) and BCSS (aHR 0.46, 95% CI 0.24-0.86) with pertuzumab treatment. Findings were similar in the HER2-single subgroup. No significant benefit of pertuzumab was seen in other subtypes. In patients with HER2-type or HER2-single-type tumors, pertuzumab significantly improved the pCR rate and decreased the risk of breast cancer mortality, which was not observed in other subtypes. BluePrint subtyping may be valuable in future studies to identify patients that are likely to be highly sensitive to HER2-targeting agents.
Sections du résumé
BACKGROUND
The introduction of pertuzumab has greatly improved pathological complete response (pCR) rates in HER2-positive breast cancer, yet effects on long-term survival have been limited and it is uncertain which patients derive most benefit. In this study, we determine the prognostic value of BluePrint subtyping in HER2-positive breast cancer. Additionally, we evaluate its use as a biomarker for predicting response to trastuzumab-containing neoadjuvant chemotherapy with or without pertuzumab.
METHODS
From a cohort of patients with stage II-III HER2-positive breast cancer who were treated with neoadjuvant chemotherapy and trastuzumab with or without pertuzumab, 836 patients were selected for microarray gene expression analysis, followed by readout of BluePrint standard (HER2, Basal and Luminal) and dual subtypes (HER2-single, Basal-single, Luminal-single, HER2-Basal, Luminal-HER2, Luminal-HER2-Basal). The associations between subtypes and pathological complete response (pCR), overall survival (OS) and breast cancer-specific survival (BCSS) were assessed, and pertuzumab benefit was evaluated within the BluePrint subgroups.
RESULTS
BluePrint results were available for 719 patients. In patients with HER2-type tumors, the pCR rate was 71.9% in patients who received pertuzumab versus 43.5% in patients who did not (adjusted Odds Ratio 3.43, 95% CI 2.36-4.96). Additionally, a significantly decreased hazard was observed for both OS (adjusted hazard ratio [aHR] 0.45, 95% CI 0.25-0.80) and BCSS (aHR 0.46, 95% CI 0.24-0.86) with pertuzumab treatment. Findings were similar in the HER2-single subgroup. No significant benefit of pertuzumab was seen in other subtypes.
CONCLUSIONS
In patients with HER2-type or HER2-single-type tumors, pertuzumab significantly improved the pCR rate and decreased the risk of breast cancer mortality, which was not observed in other subtypes. BluePrint subtyping may be valuable in future studies to identify patients that are likely to be highly sensitive to HER2-targeting agents.
Identifiants
pubmed: 37337299
doi: 10.1186/s13058-023-01664-x
pii: 10.1186/s13058-023-01664-x
pmc: PMC10280902
doi:
Substances chimiques
pertuzumab
K16AIQ8CTM
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
71Informations de copyright
© 2023. The Author(s).
Références
Transl Oncol. 2020 Apr;13(4):100756
pubmed: 32208353
Breast Cancer Res Treat. 2012 May;133(1):37-47
pubmed: 21814749
J Clin Oncol. 2021 Jul 10;39(20):2247-2256
pubmed: 33999652
Breast Cancer Res Treat. 2022 Oct;195(3):263-274
pubmed: 35984580
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Value Health. 2019 Apr;22(4):408-415
pubmed: 30975391
Cancer Treat Rev. 2020 Mar;84:101965
pubmed: 32000054
Ann Oncol. 2019 Oct 1;30(10):1674
pubmed: 31236598
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Lancet Oncol. 2018 Dec;19(12):1630-1640
pubmed: 30413379
MAbs. 2016 Oct;8(7):1361-1370
pubmed: 27380003
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Lancet Oncol. 2021 Jun;22(6):858-871
pubmed: 34019819
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
Eur J Cancer. 2018 Jan;89:27-35
pubmed: 29223479
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Breast. 2022 Oct;65:110-115
pubmed: 35921798
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
J Clin Oncol. 2021 May 1;39(13):1448-1457
pubmed: 33539215
JCO Precis Oncol. 2022 Sep;6:e2200197
pubmed: 36108259
Cancer Res. 2009 Dec 15;69(24):9330-6
pubmed: 19934333
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Breast. 2016 Oct;29:153-9
pubmed: 27498129
Breast. 2017 Aug;34 Suppl 1:S19-S26
pubmed: 28687441
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
JAMA Oncol. 2021 Jul 01;7(7):978-984
pubmed: 34014249